全球抗傳染病藥市場：第2版（Vol. III：抗病毒藥）

Abstract

This third volume of Kalorama Information' s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment:

• Nucleoside Analogs
• Protease Inhibitors
• Other Misc. Antivirals

The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides:

• Revenue Data by Infection Type
• An overview of products on the market
• Review of products in the development pipeline
• Market estimates and forecasts through 2011
• Market segmentation by geographic region
• Market share of leading suppliers
• Market share of leading products

The report also includes statistical (epidemiologic and demographic) information for viral infections by type worldwide, with special emphasis on the United States and describes the major clinical, business, and regulatory trends shaping the global and domestic markets.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. In addition, Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level as of 2006. Compound annual growth rates (CAGRs) are provided for 2006-2011 periods for each industry segment covered. Competitive analysis is provided for the year 2006. The forecasted market analysis for 2006-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• Introduction to Viruses
• Examples of Pathogenic Viruses
• Virus Function and Life History
  • Replication in DNA Viruses
  • Replication of RNA Viruses
  • Replication in Retroviruses
• Host Defenses Against Viruses
• Viral Ploys to Invade Host Cells and Circumvent Host Responses
  • Invasion of Host Cells
  • Subversion of the Immune Response
  • Avoidance of Immune Detection and Attack by Killer Cells
• HIV and AIDS
• Demographics and Statistics

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

• Overview
• Description of Products
  • Nucleoside Reverse Transcriptase Inhibitors
    • Abacavir (Ziagen, GlaxoSmithKline)
    • Didanosine (Videx, Bristol-Myers Squibb)
    • Entecavir (Baraclude, Bristol-Myers Squibb)
    • Lamividine (Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
    • Stavudine (Zerit, Bristol-Myers Squibb)
    • Telbivudine (Tyzeka, Novartis/Idenix Pharmaceuticals)
    • Zalcitabine (Hivid, Roche)
  • Zidovudine (Retrovir, GlaxoSmithKline)
  • Combination Nucleoside Reverse Transcriptase Inhibitors
    • Abacavir and Lamivudine (Epzicom/Kivexa, GlaxoSmithKline)
    • Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
    • Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
  • Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Adefovir dipivoxil (Hepsera, Gilead Sciences)
    • Tenofovir (Viread, Gilead Sciences)
  • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
    • Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
    • Emtricitabine (Emtriva, Gilead Sciences)
    • Nevirapine (Viramune, Boehringer Ingelheim)
  • Combination Non-Nucleoside Reverse Transcriptase Inhibitors
    • Efavirenz/emtricitaine tenofovir disoproxil fumarate (Atripla, Bristol-Myers Squibb/Gilead Sciences)
    • Tenofovir and emtricitabine (Truvada, Gilead Sciences)
  • DNA Polymerase Inhibitors
    • Acyclovir (Zovirax, GlaxoSmithKline)
    • Cidofovir (Vistide, Gilead Sciences)
    • Famciclovir (Famvir, Novartis)
    • Foscarnet (Foscavir, AstraZeneca)
    • Ganciclovir (Cytovene, Roche)
    • Penciclovir (Denavir, Novartis)
    • Ribavirin (Virazole, ICN Pharmaceuticals)
    • Telbivudine (Tyzeka, Idenix/Novartis)
    • Valacyclovir (Valtrex, GlaxoSmithKline)
    • Valganciclovir (Valcyte, Hoffman-LaRoche)
• Generic Drug Impact and Availability
• Research and Development
• Market Size and Growth
• Competitive Analysis

Chapter Four: Protease Inhibitors

• Overview
• Description of Products
  • Protease Inhibitors
    • Amprenavir (Agenerase, GlaxoSmithKline)
    • Atazanavir (Reyataz, Bristol-Myers Squibb)
    • Darunavir (Prezista, Tibotec Pharmaceuticals)
    • Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
    • Indinavir (Crixivan, Merck)
    • Nelfinavir (Viracept, Agouron Pharmaceuticals)
    • Ritonavir (Norvir, Abbott Laboratories)
    • Saquinavir (Fortovase, Roche; Invirase, Roche)
    • Tripanavir (Aptivus, Boehringer Ingelheim)
    • Combination Protease Inhibitors
      • Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

Chapter Five: Other Antivirals

• Overview
• Description of Products
  • Immune Response Modifiers
  • Imiquimod (Aldara, 3M Pharmaceuticals)
• Immunoglobulin G
  • Cytomegalovirus immune globulin (CytoGam, MedImmune)
• Adamantane Derivatives
  • Rimantadine HCl (Flumadine, Forest Laboratories)
  • Amantadine (Symmetrel, Endo Laboratories)
• Fusion Inhibitors
  • Enfuvirtide (Fuzeon, Trimeris/Roche)
• Interferons
  • Interferon alfacon-1 (Infergen, Amgen)
  • Interferon alpha 2a (Pegasys, Roche)
  • Interferon Alfa-n3 (Alpheron N, Hemispherx Biopharma)
  • Ribavirin + Interferon Alfa 2-a (Pegasys + Copegus, Roche)
  • Ribavirin (Rebetol, Schering-Plough; Rebetron, Schering-Plough; Ribasphere, Three Rivers Pharmaceuticals)
• Neuraminidase Inhibitors
  • Zanamivir (Relenza, GlaxoSmithKline)
  • Oseltamivir phosphate (Tamiflu, Roche)
• Immunizing Agents
  • Hepatitis B immune globulin injection (HepaGam B (Cangene)
  • Respiratory syncytial virus immune globulin (RespiGam, MedImmune)
• Monoclonal Antibodies
  • Palivizumab (Synagis, MedImmune)
• Miscellaneous Antivirals
  • Molixan, (Novelos Therapeutics/Pharma BAM)
• Generic Drug Impact and Availability
• Research and Development
  • Attachment and Fusion Inhibitors
  • Gene Therapies
  • Integrase Inhibitors
  • Maturation Inhibitors
  • Neuraminidase Inhibitors
  • Zinc Finger Inhibitors
  • Antisense Drugs
  • Cytokines
  • Monoclonal Antibodies
  • Other
• Market Size and Growth
• Competitive Analysis

Chapter Six: Issues and Trends Affecting the Antiviral Market

• Introduction
• Antiviral Drug Resistance
• Medicare Part D
• HIV Drug Cost Controversy
• Antiretroviral treatment regimens
• HIV and Women
• Global Surveillance
• Maturation Inhibitor Development
• Biochemical Prevention and Treatment of Viral Infections
• COSTS AND Funding of HIV Treatment
• Access to HIV/AIDS Treatment

Chapter Seven: Antiviral Drugs: Total Market Size and Forecast

• Overview
• Total Market Size and Forecast

Chapter Eight: Corporate Profiles

• Introduction
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline
• MedImmune, Inc.
• Merck & Company, Inc.
• Novartis Pharmaceuticals Corporation
• Roche
• Schering-Plough Corporation

APPENDIX: Company Names and Addresses

Table of exhibits

Chapter One: Executive Summary

• Table 1-1:The World Market for Antiviral Drugs 2004-2011

Chapter Two: Introduction

• Table 2-1: Host Cell Receptors
• Table 2-2: Estimated World and U.S. Incidence of Viral Infections
• Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
• Table 2-3: World Population by Selected Geographical Region, 2006-2050
• Figure 2-2: World Population by Selected Geographuhhical Region, 2006-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2006
• Table 2-3: Estimated World Population by Age and Geographical Region, 2006

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

• Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-2: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-3: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-4: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-5: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-6: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
• Table 3-7: New Generic Drug Approvals for Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors, United States, 2005-2006
• Table 3-8: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors In Development
• Table 3-9: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitor 2004-2011
• Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2004-2011
• Table 3-10: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2006
• Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2006
• Table 3-11: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2006
• Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2006
• Table 3-12: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2006
• Table 3-13: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 3-5: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Market Share by Leading Suppliers 2011
• Table 3-14: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Sales of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2006
• Figure 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2006

Chapter Four: Protease Inhibitors

• Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
• Table 4-2: Currently Available Combination Protease Inhibitors (Type, Brand, and Manufacturer)
• Table 4-3: Protease Inhibitors in Development
• Table 4-4: The Market for Protease Inhibitors 2004-2011
• Figure 4-1: Protease Inhibitor Market 2004-2011
• Table 4-5: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2006
• Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2006
• Table 4-6: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2006
• Table 4-7: Protease Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 4-4: Protease Inhibitor Market Projected Market Share by Leading Suppliers 2011
• Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2006
• Figure 4-5: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2006

Chapter Five: Other Antivirals

• Table 5-1: Currently Available Antiviral Immune Response Modifiers (Type, Brand, and Manufacturer)
• Table 5-2: Currently Available Immunoglobulin G Products (Type, Brand, and Manufacturer)
• Table 5-3: Currently Available Adamantane Derivatives (Type, Brand, and Manufacturer)
• Table 5-4: Currently Available Fusion Inhibitors (Type, Brand, and Manufacturer)
• Table 5-5: Currently Available Interferons (Type, Brand, and Manufacturer)
• Table 5-6: Currently Available Neuraminidase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-7: Currently Available Immunizing Agents (Type, Brand, and Manufacturer)
• Table 5-8: Currently Available Monoclonal Antibodies (Type, Brand, and Manufacturer)
• Table 5-9: Miscellaneous Antivirals (Type, Brand, and Manufacturer)
• Table 5-10: New Generic Drug Approvals for Other Antivirals, United States, 2005-2006
• Table 5-11: Other Antivirals in Development
• Table 5-13: The Market for Other Antivirals 2004-2011
• Figure 5-1: Other Antiviral Market 2004-2011
• Table 5-14: Other Antiviral Market Estimated Products Sales by Infection Type, 2006
• Figure 5-2: Other Antiviral Market Market Share by Infection Type, 2006
• Table 5-15: Other Antiviral Market Estimated Products Sales by Geographic Region, 2006
• Figure 5-3: Other Antiviral Market Market Share by Geographic Region, 2006
• Table 5-16: Other Antiviral Market Estimated Revenues and Market Share of Leading Suppliers 2006
• Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2006
• Table 5-17: Other Antiviral Market Projected Revenues and Market Share of Leading Suppliers 2011
• Figure 5-5: Other Antiviral Market Projected Market Share by Leading Suppliers 2011
• Table 5-18: Other Antiviral Market Estimated Sales of Other Antiviral Products 2006
• Figure 5-6: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2006

Chapter Six: Issues and Trends Affecting the Antiviral Market

• Table 6-1 People Living with HIV/AIDS by Region
• Table 6-2: AIDS Resource Needs (USS billion)
• Table 6-3: Access Needs of Adults and Children with HIV by Regions
• Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region

Chapter Seven: Antiviral Drugs: Total Market Size and Forecast

• Table 7-1: The World Market for Antiviral Drugs 2004-2011 Compound Annual Growth Rate
• Figure 7-1: The World Market for Antiviral Drugs 2004-2011
• Table 7-2: Antiviral Drug Market by Type 2004-2011
• Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2004-2011
• Figure 7-3: The World Market for Antiviral Drugs Revenues by Type 2006 and 2011